Bioinformatics and systems biology approaches to identify molecular targeting mechanism influenced by COVID-19 on

Kezhen Yang1, Jipeng Liu1, Yu Gong1

  • 1School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.

Frontiers in Immunology
|November 24, 2022
PubMed

Insights

This study reveals common immune pathways linking COVID-19 and heart failure (HF). Six hub genes were identified, offering potential therapeutic targets for both conditions.

Area of Science:

  • Immunology
  • Cardiology
  • Bioinformatics

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is linked to heart failure (HF) and increased mortality.
  • The precise mechanisms connecting COVID-19 and HF remain largely unknown.

Purpose of the Study:

  • To elucidate the shared molecular mechanisms between COVID-19 and HF.
  • To identify key genes and pathways involved in the co-occurrence of these conditions.

Main Methods:

  • Bioinformatic and systems biology approaches were employed.
  • Transcriptome analysis identified differentially expressed genes (DEGs) common to both diseases.
  • Enrichment analysis mapped DEGs to Gene Ontology terms and KEGG pathways.
  • Protein-protein interaction networks and immune cell infiltration analyses were performed.

Main Results:

  • Shared immune mechanisms include T helper cell differentiation (Th1, Th2, Th17), lymphocyte activation, and MHC class I/II complex binding.
  • Six hub genes (FCGR3A, CD69, IFNG, CCR7, CCL5, CCL4) were identified as critical links between COVID-19 and HF.
  • These hub genes are associated with various immune cells, including T cells, myeloid-derived suppressor cells, and macrophages.

Conclusions:

  • The study highlights common immune dysregulation in COVID-19 and HF.
  • Identified hub genes and associated immune cells represent potential therapeutic targets.
  • Further research into these shared pathways could lead to novel treatment strategies for patients with both conditions.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
483
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
30
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
413
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
929